2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Breast Neoplasms
34
Colorectal Neoplasms
8
Brain Neoplasms
8
Neoplasms
5
HER2-positive Breast Cancer
5
Stomach Neoplasms
4
Neoplasm Metastasis
4
Carcinoma, Non-Small-Cell Lung
4
Triple Negative Breast Neoplasms
3
Meningeal Neoplasms
3
Rectal Neoplasms
2
Multiple Myeloma
2
Lymphoma, Non-Hodgkin
2
Colonic Neoplasms
2
Adenocarcinoma Of Esophagus
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urologic Neoplasms
1
Pathologic Complete Response
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Metastatic Breast Cancer With a Isolated Brain Progression
1
Meningeal Carcinomatosis
1
Lung Neoplasms
1
Hemangiosarcoma
1
HER2-positive Metastatic Breast Cancer
1
HER2-positive Gastric Cancer
1
Gallbladder Neoplasms
1
Esophageal Neoplasms
1
Cholangiocarcinoma
1
Interventions
tucatinib
1
pralsetinib
1
pertuzumab
1
ipatasertib
1
inavolisib
1
entrectinib
1
atezolizumab
1
alectinib
1
Trastuzumab
1
Tiragolumab
1
Paclitaxel
1
Ado-Trastuzumab Emtansine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Advanced Unresectable or Metastatic Solid Malignancy
×
tucatinib
×
Clear all
NCT04632992
2025-01-08
MyTACTIC
Genentech, Inc.
Phase 2
Completed
252 enrolled
27 charts